According to details provided, this new therapeutic alternative will cost approximately 50% less than the innovative product available on the market.
The company emphasized the impact this innovation will have on the healthcare system. “The incorporation of this medication into the public health system represents a significant advancement in terms of access and equity, as it is a highly complex therapeutic alternative. This not only guarantees greater availability of the treatment for those who need it most, but also reinforces the capacity of the national healthcare system,” they specified in a statement.
The development of this plant took three years of work, including international validation processes, allowing Gador to project a reach beyond the local market.
In this regard, the company anticipated that about 80% of the production will be destined for export, focusing on regions such as Latin America, Europe, the United States, Asia, and the Middle East.
With this initiative, the laboratory not only expands its production capacity but also reinforces its positioning in a strategic segment of the global pharmaceutical industry, betting on innovation, accessibility, and international projection from Argentina.
